Maria Luisa Brandi is an expert in Endocrinology at IRCCS Ospedale San Raffaele (Italy). As of October 2026, ScienceLeadR ranks Maria Luisa Brandi in the top 1% of experts worldwide for Multiple Endocrine Neoplasia, Parathyroid Diseases and Osteoporosis. Maria Luisa Brandi has authored 1,181 publications, the most recent in 2026, and is an investigator in 12 clinical trials. SLR score: 3,759 (community average: 125). How the SLR is computed.

LeadR Profile

Maria Luisa Brandi IRCCS Ospedale San Raffaele Italy
3 759 ScienceLeadR Reputation 3759
Network Map

Endocrinology

Subspecialties: Biochemistry - Rheumatology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1986 - 2026

Source: PubMed

University of Florence

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1181

Citations

Citations: 62 459 1st author: 55 Last author: 465 Unique author: 75


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Hypomagnesemia in Hypoparathyroidism, Sensorineural Deafness, and Renal Dysplasia Syndrome Caused by Pathogenic Variants of GATA3.
PMID 42894630 — cells, gata transcription factors, promoter regions, genetic, hypoparathyroidism, transcription factors, deafness
Kidney Int Rep20260
Fracture Risk Stratification by REMS: A 5 Years Prospective Longitudinal Multicentre Study.
PMID 42816604
Calcif Tissue Int20260
Vitamin D in coronary heart disease: a Mendelian randomization meta-analysis of data stratified by 25(OH)D levels.
PMID 42768817 — vitamin d, heart diseases, vitamins, heart, coronary disease, random allocation
Cardiovasc Res20260
Genetic testing and reporting: What the endocrinologists should know and can expect (Joint position paper of the ENDO-ERN).
PMID 42744303 — research design, high-throughput nucleotide sequencing, genetic testing, laboratories, workflow, endocrinologists, hormones
Eur J Endocrinol20260
Clinical guidance on evaluation and management of bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS): an IOF position statement.
PMID 42709184 — comorbidity, osteoporosis, risk factors, therapeutics, monoclonal gammopathy of undetermined significance
Osteoporos Int20260

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 7
N/A 3
Phase 2 1
Phase 4 1

By status:

Completed 9
Active not recruiting 1
Recruiting 1
Terminated 1

By type:

Interventional 9
Observational 3

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 0
multicentricup10 7

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map